Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialMathias Rummel, Wolfram Brugger, Martina Stauch et al.|The Lancet|2013Cited by 1.5k
Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).Mathias Rummel, Wolfram Brugger, N. Niederle et al.|Blood|2009Cited by 157
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.Mathias Rummel, Wolfram Brugger, Georg Maschmeyer et al.|Journal of Clinical Oncology|2017Cited by 83
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.Mathias Rummel, N. Niederle, Georg Maschmeyer et al.|Journal of Clinical Oncology|2012Cited by 50
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)Mathias Rummel, Juergen Barth, Ulrich Kaiser et al.|Blood|2010Cited by 41